Trial Profile
Phase I/II Study of Combination Therapy With MRA (Tocilizumab) and Gemcitabine for Unresectable Locally Advanced or Metastatic Pancreatic Cancer
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 20 Nov 2018
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Tocilizumab (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Chugai Pharmaceutical
- 27 May 2016 New trial record